International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 59

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 59

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 59

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

alaninati brivanibum

brivanib alaninate — (2*R*)-1-({4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-5-methylpyrrolo=[2,1-*f*][1,2,4]triazin-6-yl}oxy)propan-2-yl L-alaninate

alaninate de brivanib — L-alaninate de (2*R*)-1-({4-[(4-fluoro-2-méthyl-1*H*-indol-5-yl)oxy]-5-méthylpyrrolo[2,1-*f*][1,2,4]triazin-6-yl}oxy)propan-2-yle

alaninato de brivanib — L-alaninato de (2*R*)-1-({4-[(4-fluoro-2-metil-1*H*-indol-5-il)oxi]-5-metilpirrolo[2,1-*f*][1,2,4]triazin-6-il}oxi)propan-2-ilo

$C_{22}H_{24}FN_5O_4$



albiglutidum*

albiglutide — ([8-glycine]human glucagon-like peptide 1-(7-36)-peptidyl)([8-glycine]human glucagon-like peptide 1-(7-36)-peptidyl)(human serum albumin (585 residues))

albiglutide — ([8-glycine]peptide 1 analogue au glucagon humain-(7-36)-peptidyl)([8-glycine]peptide 1 analogue au glucagon humain-(7-36)-peptidyl)(albumine sérique humaine (585 aminoacides))

albiglutida — ([8-glicina]péptido1 análogo al glucagón humano-(7-36)-peptidil)([8-glicina]péptido 1 análogo al glucagón humano-(7-36)-peptidil)(albumina séria humana (585 aminoácidos))

$C_{3232}H_{5032}N_{864}O_{979}S_{41}$

```
HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR HGEGTFTSDV SSYLEGQAAK 50
EFIAWLVKGR DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 100
KLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC 150
CAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY 200
EIARRHPYFY APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK 250
ASSAKQRLKC ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK 300
VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI 350
AEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD 400
YSVVLLLRLA KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ 450
NCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 500
PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA 550
LEVDETYVPK EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT 600
KEQLKAVMDD FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL      645
```

Disulfide bridges location Position des ponts disulfure / Posiciones de los puentes disulfuro
113-122 135-151 150-161 184-229 228-237 260-306 305-313 325-339 338-349
376-421 420-429 452-498 497-508 521-537 536-547 574-619 618-627

albinterferonum alfa-2b*

albinterferon alfa-2b — human serum albumin (585 residues) fusion protein with human interferon α-2b (165 residues)

albinterféron alfa-2b — protéine de fusion entre l'albumine sérique humaine (585 aminoacides) et l'interféron α-2b humain (165 aminoacides)

albinterferón alfa 2b — proteína de fusión entre la albumina sérica humana (585 aminoácidos) y el interferón α-2b humano (165 aminoácidos)

$C_{3796}H_{5937}N_{1015}O_{1143}S_{50}$

```
DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 100
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250
LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 350
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 450
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGLCDLPQ THSLGSRRTL 600
MLLAQMRRIS LFSCLKDRHD FGFPQEEFGN QFQKAETIPV LHEMIQQIFN 650
LFSTKDSSAA WDETLLDKFY TELYQQLNDL EACVIQGVGV TETPLMKEDS 700
ILAVRKYFQR ITLYLKEKKY SPCAWEVVRA EIMRSFSLST NLQESLRSKE 750
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279
278-289 316-361 360-369 392-438 437-448 461-477 476-487 514-559
558-567 586-683 614-723

Glycosylation sites : N-318 T-691

anamorelinum

anamorelin — (3*R*)-3-benzyl-*N*,*N'*,*N'*-trimethyl-1-{2-methylalanyl-D-tryptophyl}=piperidine-3-carbohydrazide

anamoréline — (3*R*)-3-benzyl-*N*,*N'*,*N'*-triméthyl-1-(2-méthylalanyl-D-tryptophyl)=pipéridine-3-carbohydrazide

anamorelina — (3*R*)-3-bencil-*N*,*N'*,*N'*-trimetil-1-{2-metilalanil-D-triptofil}piperidina-3-carbohidrazida

$C_{31}H_{42}N_6O_3$



apremilastum

apremilast — *N*-{2-[(1*S*)-1-(3-ethoxy-4-methoxyphenyl)-2-(methanesulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acetamide

aprémilast — *N*-{2-[(1*S*)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthanesulfonyl)éthyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl}acétamide

apremilast — *N*-{2-[(1*S*)-1-(3-etoxi-4-metoxifenil)-2-(metansulfonil)etil]-1,3-dioxo-2,3-dihidro-1*H*-isoindol-4-il}acetamida

$C_{22}H_{24}N_2O_7S$



arbaclofenum placarbilum

arbaclofen placarbil	(3*R*)-3-(4-chlorophenyl)-4-[({(1*S*)-2-methyl-1-[(2-methylpropanoyl)=oxy]propoxy}carbonyl)amino]butanoic acid
arbaclofène placarbil	acide (3*R*)-3-(4-chlorophényl)-4-[({(1*S*)-2-méthyl-1-[(2-méthylpropanoyl)oxy]propoxy}carbonyl)amino]butanoïque
arbaclofeno placarbilo	ácido (3*R*)-3-(4-clorofenil)-4-[({(1*S*)-2-metil-1-[(2-metilpropanoil)=oxi]propoxi}carbonil)amino]butanoico

$C_{19}H_{26}ClNO_6$



arterolanum

arterolane	*N*-(2-amino-2-methylpropyl)-2-{*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexan]-4"-yl}acetamide
artérolane	*N*-(2-amino-2-methylpropyl)-2-{*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexan]-4"-yl}acétamide
arterolano	*N*-(2-amino-2-metilpropil)-2-{*cis*-dispiro[adamantano-2,3'-[1,2,4]trioxolano-5',1"-ciclohexan]-4"-il}acetamida

$C_{22}H_{36}N_2O_4$



azilsartanum medoxomilum

azilsartan medoxomil	(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl}-1*H*-benzimidazol-7-carboxylate
azilsartan médoxomil	2-éthoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphényl-4-yl]méthyl}-1*H*-benzimidazole-7-carboxylate de (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle

azilsartán medoxomilo

2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)-1,1'-bifenil-4-il]metil}-1*H*-benzoimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo

$C_{30}H_{24}N_4O_8$



azoximeri bromidum

azoximer bromide

poly{[1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide]ethylene-*co*-[(piperazin-1,4-diyl 1-oxide)ethylene]}

bromure d'azixomère

poly{[bromure de 1-(carboxyméthyl)pipérazin-1-ium-1,4-diyl]éthylène-*co*-[(1-oxyde de pipérazine-1,4-diyl)éthylène]}

bromuro de azoxímero

poly{[bromuro de 1-(carboximetil)piperazin-1-io-1,4-diil]etileno-*co*-[(1-óxido de piperazin-1,4-diil)etileno]}

$[[C_8H_{15}BrN_2O_2]_x[C_6H_{12}N_2O]_y]_n$



begacestatum

begacestat

5-chloro-*N*-[(2*S*)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide

bégacestat

5-chloro-*N*-[(2*S*)-4,4,4-trifluoro-1-hydroxy-3-(trifluorométhyl)butan-2-yl]thiophène-2-sulfonamide

begacestat

5-cloro-*N*-[(2*S*)-4,4,4-trifluoro-1-hidroxi-3-(trifluorometil)butan-2-il]tiofeno-2-sulfonamida

$C_9H_8ClF_6NO_3S_2$



belataceptum

belatacept — [Tyr^{29},Glu^{104},Gln^{125},Ser^{130},Ser^{136},Ser^{139},Ser^{148}](antigen CTLA-4 human-3-126]-peptide (fragment containing the human extracellular domain) fusion protein with immunoglobulin G1-[233 amino acids from the C-terminal of the heavy chain]-peptide (fragment containing the human monoclonal Fc domain), bimolecular (120→120')-disulfide

bélatacept — (120→120')-disulfure bimoléculaire de [Tyr^{29},Glu^{104},Gln^{125},Ser^{130},Ser^{136},Ser^{139},Ser^{148}](antigène CTLA-4 humain-[3-126]-peptide (fragment contenant le domaine extracellulaire) protéine de fusion avec l'immunoglobuline G1-[233 aminoacides *C*-terminaux de la chaîne lourde]-peptide (fragment contenant le domaine Fc de l'anticorps monoclonal humain))

belatacept — (120→120')-disulfuro bimolecular de [Tyr^{29},Glu^{104},Gln^{125},Ser^{130},Ser^{136},Ser^{139},Ser^{148}](antígeno CTLA-4 humano-[3-126]-péptido (fragmento que contiene el dominio extracelular) proteína de fusión con la inmunoglobulina G1-[233 aminoácidos *C*-terminales de la cadena pesada]-péptido (fragmento que contiene el dominio Fc del anticuerpo monoclonal humano))

$C_{3508}H_{5440}N_{922}O_{1096}S_{32}$

```
MHVAQPAVVL  ASSRGIASFV
CEYASPGKYT  EVRVTVLRQA
DSQVTEVCAA  TYMMGNELTF
LDDSICTGTS  SGNQVNLTIQ
GLRAMDTGLY  ICKVELMYPP
PYYEGIGNGT  QIYVIDPEPC
PDSDQEPKSS  DKTHTSPPSP
APELLGGSSV  FLFPPKPKDT
LMISRTPEVT  CVVVDVSHED
PEVKFNWYVD  GVEVHNAKTK
PREEQYNSTY  RVVSVLTVLH
QDWLNGKEYK  CKVSNKALPA
PIEKTISKAK  GQPREPQVYT
LPPSRDELTK  NQVSLTCLVK
GFYPSDIAVE  WESNGQPENN
YKTTPPVLDS  DGSFFLYSKL
TVDKSRWQQG  NVFSCSVMHE
ALHNHYTQKS  LSLSPGK    2
```

* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

belinostatum

belinostat — *N*-hydroxy-3-[3-(*N*-phenylsulfamoyl)phenyl]prop-2-enamide

bélinostat — *N*-hydroxy-3-[3-(phénylsulfamoyl)phényl]prop-2-ènamide

belinostat — *N*-hidroxi-3-{3-[(fenilsulfamoil]fenil}prop-2-enamida

$C_{15}H_{14}N_2O_4S$



boceprevirum

boceprevir — (1*R*,2*S*,5*S*)-*N*-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]-3-{(2*S*)-2-[(*tert*-butylcarbamoyl)amino]-3,3-dimethylbutanoyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

bocéprévir — (1*R*,2*S*,5*S*)-*N*-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]-3-{(2*S*)-2-[(*tert*-butylcarbamoyl)amino]-3,3-diméthylbutanoyl}-6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

boceprevir — (1*R*,2*S*,5*S*)-*N*-[(2Ξ)-4-amino-1-ciclobutil-3,4-dioxobutan-2-il)]-3-{(2*S*)-2-[(*terc*-butilcarbamoil)amino]-3,3-dimetilbutanoil}-6,6-dimetil-3-azabiciclo[3.1.0]hexano-2-carboxamida

$C_{27}H_{45}N_5O_5$



canakinumabum*

canakinumab — immunoglobulin G1, anti-[*Homo sapiens* interleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (*Homo sapiens* VH-IGHG1*03) (221-214')-disulfide with kappa light chain (*Homo sapiens* V-KAPPA-IGKC*01); (227-227'':230-230'')-bisdisulfide dimer

canakinumab — immunoglobuline G1, anti-[*Homo sapiens* interleukine 1, beta (IL1B)] anticorps monoclonal humain ACZ885; chaîne lourde gamma1 (*Homo sapiens* VH-IGHG1*03) (221-214')-disulfure avec la chaîne légère kappa (*Homo sapiens* V-KAPPA-IGKC*01); dimère (227-227'':230-230'')-bisdisulfure

canakinumab — inmunoglobulina G1, anticuerpo monoclonal humano ACZ885 anti-[interleukina 1 de *Homo sapiens*, beta (IL1B)]; cadena pesada gamma1 (*Homo sapiens* VH-IGHG1*03) (221-214')-disulfuro con la cadena ligera kappa (*Homo sapiens* V-KAPPA-IGKC*01); dímero (227-227'':230-230'')-bisdisulfuro

$C_{6452}H_{9958}N_{1722}O_{2010}S_{42}$

carfilzomibum

carfilzomib — {(2*S*)-2-[(morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N^1-{(2*S*)-1-[(2*R*)-2-methyloxiran-2-yl]-4-methyl-1-oxopentan-2-yl}-L-phenylalaninamide

carfilzomib — {(2*S*)-2-[(morpholin-4-yl)acétamido]-4-phénylbutanoyl}-L-leucyl-N^1-{(2*S*)-1-[(2*R*)-2-méthyloxiran-2-yl]-4-méthyl-1-oxopentan-2-yl}-L-phénylalaninamide

carfilzomib — {(2*S*)-2-[(morfolin-4-il)acetamido]-4-fenilbutanoil}-L-leucil-N^1-{(2*S*)-1-[(2*R*)-2-metiloxiran-2-il]-4-metil-1-oxopentan-2-il}-L-fenilalaninamida

$C_{40}H_{57}N_5O_7$



ceftarolinum fosamilum

ceftaroline fosamil — (6*R*,7*R*)-7-{(2*Z*)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido}-3-{[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

céftaroline fosamil — (6R,7R)-7-{(2*Z*)-2-(éthoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acétamido}-3-{[4-(1-méthylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

ceftarolina fosamilo — (6*R*,7*R*)-7-{(2*Z*)-2-(etoxiimino)-2-[5-(fosfonoamino)-1,2,4-tiadiazol-3-il]acetamido}-3-{[4-(1-metilpiridin-1-io-4-il)-1,3-tiazol-2-il]sulfanil}-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxilato

$C_{22}H_{21}N_8O_8PS_4$



cenersenum

cenersen — antisense oligonucleotide inhibitor of p53 expression
2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxycytidine

cénersen — oligonucléotide antisense inhibiteur de l'expression de p53
2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxycytidine

cenersén — oligonucleótido antisentido inhibidor de la expresión de p53
2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxicitidina

$C_{187}H_{226}N_{62}O_{103}P_{19}S_{19}$

cholini fenofibratum

choline fenofibrate — 2-hydroxy-*N*,*N*,*N*-trimethylethanaminium 2-[4-(4-chlorobenzoyl)=phenoxy]-2-methylpropanoate

fénofibrate de choline — 2-[4-(4-chlorobenzoyl)phénoxy]-2-méthylpropanoate de 2-hydroxy-*N*,*N*,*N*-triméthyléthanaminium

fenofibrato de colina — 2-[4-(4-clorobenzoil)fenoxi]-2-metilpropanoato de 2-hidroxi-*N*,*N*,*N*-trimetiletanaminio

$C_5H_{14}NO^+.C_{17}H_{14}ClO_4^-$



cinaciguatum

cinaciguat	4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)phenyl]methoxy}=phenyl)ethyl]amino}methyl)benzoic acid
cinaciguat	acide 4-({(4-carboxybutyl)[2-(2-{[4-(2-phényléthyl)phényl]méthoxy}=phényl)éthyl]amino}méthyl)benzoïque
cinaciguat	ácido 4-({(4-carboxibutil)[2-(2-{[4-(2-feniletil)fenil]metoxi}fenil)=etil]amino}metil)benzoico

$C_{36}H_{39}NO_5$



contusugenum ladenovecum*

contusugene ladenovec	(Recombinant) replication restricted adenovirus (type 5) vector, E1 deleted, partial E3 deletion, containing/expressing a wild type p53 gene driven by a cytomegalovirus promoter
contusugène ladénovec	Vecteur adénovirus (type 5) recombinant défectif, délété de E1 et partiellement de E3, contenant le gène p53 sauvage sous le contrôle du promoteur cytomégalovirus
contusugén ladenovec	Vector adenovirus (tipo 5) recombinante defectivo, con deleción de E1 y parcialmente de E3, que contiene el gen p53 salvaje controlado por el promotor de cytomegalovirus

dapagliflozinum

dapagliflozin	(1*S*)-1,5-anhydro-1-*C*-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol
dapagliflozine	(1*S*)-1,5-anhydro-1-*C*-{4-chloro-3-[(4-éhoxyphényl)méthyl]phényl}-D-glucitol
dapagliflozina	(1*S*)-1,5-anhidro-1-*C*-{4-cloro-3-[(4-etoxifenil)metil]fenil}-D-glucitol

$C_{21}H_{25}ClO_6$



delimotecanum

delimotecan — poly{[2-*O*-(carboxymethyl)-α-D-glucopyranosyl-(1→6)]-*co*-[2-*O*-(15-{[(4*S*)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl]oxy}-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecyl)-α-D-glucopyranosyl-(1→6)]-*co*-[α-D-glucopyranosyl-(1→6)]}

délimotécan — poly{[2-*O*-(carboxyméthyl)-α-D-glucopyranosyl-(1→6)]-*co*-[2-*O*-(15-{[(4*S*)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-9-yl]oxy}-2,5,8,11-tétraoxo-3,6,9,12-tétraazapentadécyl)-α-D-glucopyranosyl-(1→6)]-*co*-[α-D-glucopyranosyl-(1→6)]}

delimotecán — poli{[2-*O*-(carboximetil)-α-D-glucopiranosil-(1→6)]-*co*-[2-*O*-(15-{[(4*S*)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-il]oxi}-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecil)-α-D-glucopiranosil-(1→6)]-*co*-[α-D-glucopiranosil-(1→6)]}

$[C_{39}H_{46}N_6O_{14}[C_6H_{10}O_5]_x[C_8H_{12}O_7]_y]_n$



dovitinibum

dovitinib — 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazole-2-yl]quinolin-2(1*H*)-one

dovitinib — 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1*H*-benzimidazol-2-yl]quinoléin-2(1*H*)-one

dovitinib — 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1*H*-benzoimidazol-2-il]quinolin-2(1*H*)-ona

$C_{21}H_{21}FN_6O$



eldecalcitolum

eldecalcitol	(5*Z*,7*E*)-2β-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1α,3β,25-triol
eldécalcitol	(5*Z*,7*E*)-2β-(3-hydroxypropoxy)-9,10-sécocholesta-5,7,10(19)-triène-1α,3β,25-triol
eldecalcitol	(5*Z*,7*E*)-2β-(3-hidroxipropoxi)-9,10-secocolesta-5,7,10(19)-trieno-1α,3β,25-triol

$C_{30}H_{50}O_5$



elvitegravirum

elvitegravir	6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2*S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
elvitégravir	acide 6-[(3-chloro-2-fluorophényl)méthyl]-1-[(2*S*)-1-hydroxy-3-méthylbutan-2-yl]-7-méthoxy-4-oxo-1,4-dihydroquinoline-3-carboxylique
elvitegravir	ácido 6-[(3-cloro-2-fluorofenil)metil]-1-[(2*S*)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{23}H_{23}ClFNO_5$



epetirimodum

epetirimod	1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-4-amine
épétirimod	1-(2-méthylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphtyridin-4-amine
epetirimod	1-(2-metilpropil)-1*H*-imidazo[4,5-*c*][1,5]naftiridin-4-amina

$C_{13}H_{15}N_5$



epoetinum kappa

epoetin kappa	1-165-erythropoietin (human JR-013), glycoform κ
époétine kappa	érythropoïétine (humaine JR-013)-(1-165), glycoforme κ
epoetina kappa	1-165-eritropoyetina (humana JR-013), glicoforma κ

$C_{809}H_{1301}N_{229}O_{240}S_5$

eribulinum

eribulin	(2*R*,3*R*,3a*S*,7*R*,8a*S*,9*S*,10a*R*,11*S*,12*R*,13a*R*,13b*S*,15*S*,18*S*,21*S*,24*S*,26*R*,28*R*,29a*S*)-2-[(2*S*)-3-amino-2-hydroxypropyl]-3-methoxy-26-methyl-20,27-dimethylidenehexacosahydro-11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9*H*,15*H*-furo[3,2-*i*]furo[2',3':5,6]pyrano[4,3-*b*][1,4]dioxacyclopentacosin-5(4*H*)-one
éribuline	(2*R*,3*R*,3a*S*,7*R*,8a*S*,9*S*,10a*R*,11*S*,12*R*,13a*R*,13b*S*,15*S*,18*S*,21*S*,24*S*,26*R*,28*R*,29a*S*)-2-[(2*S*)-3-amino-2-hydroxypropyl]-3-méthoxy-26-méthyl-20,27-diméthylidènehexacosahydro-11,15:18,21:24,28-triépoxy-7,9-éthano-12,15-méthano-9*H*,15*H*-furo[3,2-*i*]furo[2',3':5,6]pyrano[4,3-*b*][1,4]dioxacyclopentacosin-5(4*H*)-one
eribulina	(2*R*,3*R*,3a*S*,7*R*,8a*S*,9*S*,10a*R*,11*S*,12*R*,13a*R*,13b*S*,15*S*,18*S*,21*S*,24*S*,26*R*,28*R*,29a*S*)-2-[(2*S*)-3-amino-2-hidroxipropil]-26-metil-20,27-dimetilideno-3-metoxihexacosahidro-11,15:18,21:24,28-triepoxi-7,9-etano-12,15-metano-9*H*,15*H*-furo[3,2-*i*]furo=[2',3':5,6]pirano[4,3-*b*][1,4]dioxaciclopentacosin-5(4*H*)-ona

$C_{40}H_{59}NO_{11}$



faxeladolum

faxeladol	3-[(1*R*,2*R*)-2-(dimethylaminomethyl)cyclohexyl]phenol
faxéladol	3-{(1*R*,2*R*)-2-[(diméthylamino)méthyl]cyclohexyl}phenol
faxeladol	3-[(1*R*,2*R*)-2-(dimetilaminometil)ciclohexil]fenol

$C_{15}H_{23}NO$



ferricum carboxymaltosum

ferric carboxymaltose	poly[D-glucopyranosyl(1→4)]-D-gluconic acid complex of hydrated iron(III) oxide
carboxymaltose ferrique	complexe d'oxide de fer(III) et d'acide poly[D-glucopyranosyl(1→4)]-D-gluconique hydraté
carboximaltosa férrica	ácido poli[D-glucopiranosil(1→4)]-D-glucónico complejo de óxido de hierro(III) hidratado

$FeIII_w([C_6H_{10}O_5]_aC_6H_{11}O_7)x(OH)_yO_z.nH_2O$

flovagatranum

flovagatran	(1*R*)-1-{*N*-[(benzyloxy)carbonyl]-D-phenylalanyl-L-prolinamido}=butylboronic acid
flovagatran	acide (1*R*)-1-({*N*-[(benzyloxy)carbonyl]-D-phénylalanyl-L-prolyl}=amino)butylboronique
flovagatrán	ácido (1*R*)-1-{*N*-[(benciloxi)carbonil]-D-fenilalanil-L-prolinamido}=butilborónico

$C_{27}H_{36}BN_3O_7$



gantenerumabum*

gantenerumab — immunoglobulin G1, anti-(human beta-amyloid peptides Aβ42 and Aβ40) human monoclonal antibody; gamma1 heavy chain (*Homo sapiens* VH-IGHG1) (229-215')-disulfide with kappa light chain (*Homo sapiens* V-KAPPA-IGKC); (235-235":238-238")-bisdisulfide dimer

ganténérumab — immunoglobuline G1, anti-(peptides beta-amyloides Aβ42 et Aβ40 humains) anticorps monoclonal humain; chaîne lourde gamma1 (*Homo sapiens* VH-IGHG1) (229-215')-disulfure avec la chaîne légère kappa (*Homo sapiens* V-KAPPA-IGKC); dimère (235-235":238-238")-bisdisulfure

gantenerumab — inmunoglobulina G1, anticuerpo monoclonal humano anti-(péptidos beta-amiloides Aβ42 et Aβ40 humanos); cadena pesada gamma1 (*Homo sapiens* VH-IGHG1) (229-215')-disulfuro con la cadena ligera kappa (*Homo sapiens* V-KAPPA-IGKC); dimero (235-235":238-238")-bisdisulfuro

γ1- heavy chain / Chaîne lourde γ1 / Cadena pesada γ1

```
QVELVESGGG LVQPGGSLRL S**C**AASGFTFS SYAMSWVRQA PGKGLEWVSA 50
I**N**ASGTRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYY**C**ARGK 100
GNTHKPYGYV RYFDVWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LG**C**LVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYI**C**N VNHKPSNTKV DKKVEPKS**C**D KTHT**C**PP**C**PA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVT**C** VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYK**C** KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSRDELTKN QVSLT**C**LVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFS**C**SVMHEA LHNHYTQKSL 450
SLSPGK                                                    456
```

κ-light chain / Chaîne légère κ / Cadena ligera κ

```
DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFATYYCL QIYNMPITFG  100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK  150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ  200
GLSSPVTKSF NRGE**C**                                     215
```

The position of cysteine (C) residues that form disulphide bridges and asparagine residues that are *N*-glycosylated are in bold.

golotimodum

golotimod — D-γ-glutamyl-L-tryptophan

golotimod — D-γ-glutamyl-L-tryptophane

golotimod — D-γ-glutamil-L-triptófano

$C_{16}H_{19}N_3O_5$



ibalizumabum*

ibalizumab — immunoglobulin G4, anti-(human CD4) humanized monoclonal antibody Hu5A8 (TNX-355); gamma4 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR [8.8.15] from clone Mu5A8)-*Homo sapiens* IGHG4*01] (136-219')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR [12.3.8] from clone Mu5A8)-*Homo sapiens* IGKC*01] ; (228-228':231-231")-bisdisulfide dimer

ibalizumab — immunoglobuline G4, anti-(CD4 humain) anticorps monoclonal humanisé Hu5A8 (TNX-355); chaîne lourde gamma4 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR [8.8.15] du clone 5A8)-*Homo sapiens* IGHG4] (136-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR [12.3.8] du clone Mu5A8)-*Homo sapiens* IGKC*01]; dimère (228-228":231-231")-bisdisulfure

ibalizumab — inmunoglobulina G4, anti-(CD4 humano) anticuerpo monoclonal humanizado Hu5A8 (TNX-355); cadena pesada gamma4 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR [8.8.15] del clon 5A8)-*Homo sapiens* IGHG4] (136-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR [12.3.8] del clon Mu5A8)-*Homo sapiens* IGKC*01]; dímero (228-228":231-231")-bisdisulfuro

Ig γ4-heavy chain / Chaîne lourde Ig γ4 / Cadena pesada Ig γ4

```
QVQLQQSGPE  VVKPGASVKM  SCKASGYTFT  SYVIHWVRQK  PGQGLDWIGY  50
INPYNDGTDY  DEKFKGKATL  TSDTSTSTAY  MELSSLRSED  TAVYYCAREK  100
DNYATGAWFA  YWGQGTLVTV  SSASTKGPSV  FPLAPCSRST  SESTAALGCL  150
VKDYFPEPVT  VSWNSGALTS  GVHTFPAVLQ  SSGLYSLSSV  VTVPSSSLGT  200
KTYTCNVDHK  PSNTKVDKRV  ESKYGPPCPS  CPAPEFLGGP  SVFLFPPKPK  250
DTLMISRTPE  VTCVVVDVSQ  EDPEVQFNWY  VDGVEVHNAK  TKPREEQFNS  300
TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKGL  PSSIEKTISK  AKGQPREPQV  350
YTLPPSQEEM  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL  400
DSDGSFFLYS  RLTVDKSRWQ  EGNVFSCSVM  HEALHNHYTQ  KSLSLSLGK   449
```

Ig κ-light chain / Chaîne légère Ig κ / Cadena ligera Ig κ

```
DIVMTQSPDS  LAVSLGERVT  MNCKSSQSLL  YSTNQKNYLA  WYQQKPGQSP  50
KLLIYWASTR  ESGVPDRFSG  SGSGTDFTLT  ISSVQAEDVA  VYYCQQYYSY  100
RTFGGGTKLE  IKRTVAAPSV  FIFPPSDEQL  KSGTASVVCL  LNNFYPREAK  150
VQWKVDNALQ  SGNSQESVTE  QDSKDSTYSL  SSTLTLSKAD  YEKHKVYACE  200
VTHQGLSSPV  TKSFNRGEC                                      219
```

idrabiotaparinuxum natricum

idrabiotaparinux sodium — nonasodium methyl (2-deoxy-3,4-di-*O*-methyl-2-{6-[5-(2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido]=hexanamido}-6-*O*-sulfo-α-D-glucopyranosyl)-(1→4)-(2,3-di-*O*-methyl-β-D-glucopyranosyluronate)-(1→4)-(2,3,6-tri-*O*-sulfo-α-D-glucopyranoside)-(1→4)-(2,3-di-*O*-methyl-α-L-idopyranosyluronate)-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranoside

idrabiotaparinux sodique — 2-déoxy-3,4-di-*O*-méthyl-2-{[6-({5-[(3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*-thiéno[3,4-*d*]imidazol-4-yl]pentanoyl}amino)hexanoyl]amino}-6-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3-di-*O*-méthyl-β-D-glucopyranuronosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3-di-*O*-méthyl-α-L-idopyranuronosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranoside de méthyle nonasodique

idrabiotaparinux sódico

2-desoxy-3,4-di-*O*-metil-2-{[6-({5-[(3a*S*,4*S*,6a*R*)-2-oxohexahidro-1*H*-tieno[3,4-*d*]imidazol-4-il]pentanoil}amino)hexanoil]amino}-6-*O*-sulfo-α-D-glucopiranosil-(1→4)-2,3-di-*O*-metil-β-D-glucopiranuronosil-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopiranosil-(1→4)-2,3-di-*O*-metil-α-L-idopiranuronosil-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopiranosido de metilo y nonasodico

$C_{53}H_{79}N_4Na_9O_{51}S_8$



laropiprantum

laropiprant

[(3*R*)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[*b*]indol-3-yl]acetic acid

laropiprant

acide [(3*R*)-4-[(4-chlorophényl)méthyl]-7-fluoro-5-(méthanesulfonyl)-1,2,3,4-tétrahydrocyclopenta[*b*]indol-3-yl]acétique

laropiprant

ácido [(3*R*)-4-[(4-clorofenil)metil]-7-fluoro-5-(metanosulfonil)-1,2,3,4-tetrahidrociclopenta[*b*]indol-3-il]acético

$C_{21}H_{19}ClFNO_4S$



levamlodipinum

levamlodipine

3-ethyl 5-methyl (4*S*)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

lévamlodipine

(4*S*)-2-[(2-aminoéthoxy)méthyl]-4-(2-chlorophényl)-6-méthyl-1,4-dihydropyridine-3,5-dicarboxylate de 3-éthyle et de 5-méthyle

levamlodipino

(4*S*)-2-[(2-aminoetoxi)metil]-4-(2-clorofenil)-6-metil-1,4-dihidropiridina-3,5-dicarboxilato de 3-etilo y 5-metilo

$C_{20}H_{25}ClN_2O_5$



lonaprisanum

lonaprisan — 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-5,9-dien-3-one

lonaprisan — 11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-prégna-5,9-dién-3-one

lonaprisán — 11β-(4-acetilfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-17α-pregna-5,9-dien-3-ona

$C_{28}H_{29}F_5O_3$



metenkefalinum

metenkefalin — L-tyrosylglycylglycyl-L-phenylalanyl-L-methionine β-endorphin human-(1-5)-peptide

métenkefaline — L-tyrosylglycylglycyl-L-phénylalanyl-L-méthionine β-endorphine humaine-(1-5)-peptide

metencefalina — L-tirosilglicilglicil-L-fenilalanil-L-metionina β-endorfina humana-(1-5)-peptido

$C_{27}H_{35}N_5O_7S$

H−L-Tyr−Gly−Gly−L-Phe−L-Met−OH

milveterolum

milveterol — *N*-{2-hydroxy-5-[(1*R*)-1-hydroxy-2-{[2-(4-{[(2*R*)-2-hydroxy-2-phenylethyl]amino}phenyl)ethyl]amino}ethyl]phenyl}formamide

milvétérol — *N*-{2-hydroxy-5-[(1*R*)-1-hydroxy-2-{[2-(4-{[(2*R*)-2-hydroxy-2-phényléthyl]amino}phényl)éthyl]amino}éthyl]phényl}formamide

milveterol — *N*-{2-hidroxi-5-[(1*R*)-1-hidroxi-2-{[2-(4-{[(2*R*)-2-hidroxi-2-feniletil]amino}fenil)etil]amino}etil]fenil}formamida

$C_{25}H_{29}N_3O_4$



motesanibum

motesanib — *N*-(3,3-dimethyl-2,3-dihydro-1*H*-indol-6-yl)-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide

motésanib — *N*-(3,3-diméthyl-2,3-dihydro-1*H*-indol-6-yl)-2-{[(pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

motesanib — *N*-(3,3-dimetil-2,3-dihidro-1*H*-indol-6-il)-2-{[(piridin-4-il)metil]amino}piridina-3-carboxamida

$C_{22}H_{23}N_5O$



nepiderminum

nepidermin — human epidermal growth factor, recombinant DNA origin

népidermine — facteur humain de croissance épidermique, origine ADN recombinant

nepidermina — factor de crecimiento epidérmico humano; origen: ADN recombinante

$C_{270}H_{401}N_{73}O_{83}S_7$



neratinibum

neratinib — (2*E*)-*N*-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

nératinib — (2*E*)-*N*-[4-({3-chloro-4-[(pyridin-2-yl)méthoxy]phényl}amino)-3-cyano-7-éthoxyquinoléin-6-yl]-4-(diméthylamino)but-2-énamide

neratinib — (2*E*)-*N*-[4-({3-cloro-4-[(piridin-2-yi)metoxi]fenil}amino)-3-ciano-7-etoxiquinolin-6-il]-4-(dimetilamino)but-2-enamida

$C_{30}H_{29}ClN_6O_3$



perampanelum

perampanel	2-(6'-oxo-1'-phenyl-1',6'-dihydro[2,3'-bipyridin]-5'-yl)benzonitrile
pérampanel	2-(6'-oxo-1'-phenyl-1',6'-dihydro[2,3'-bipyridin]-5'-yl)benzonitrile
perampanel	2-(1'-fenil-6'-oxo-1',6'-dihidro[2,3'-bipiridin]-5'-il)benzonitrilo

$C_{23}H_{15}N_3O$



peretinoinum

peretinoin	(2*E*,4*E*,6*E*,10*E*)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid
pérétinoïne	acide (2*E*,4*E*,6*E*,10*E*)-3,7,11,15-tétraméthylhexadéca-2,4,6,10,14-penténoïque
peretinoína	ácido (2*E*,4*E*,6*E*,10*E*)-3,7,11,15-tetrametilhexadeca-2,4,6,10,14-pentaenoico

$C_{20}H_{30}O_2$



pexacerfontum

pexacerfont	*N*-[(2*R*)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine
pexacerfont	*N*-[(2*R*)-butan-2-yl]-8-(6-méthoxy-2-méthylpyridin-3-yl)-2,7-diméthylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine
pexacerfont	*N*-[(2*R*)-butan-2-il]-8-(6-metoxi-2-metilpiridin-3-il)-2,7-dimetilpirazolo[1,5-*a*][1,3,5]triazin-4-amina

$C_{18}H_{24}N_6O$



pimavanserinum

pimavanserin	1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea
pimavansérine	1-[(4-fluorophényl)méthyl]-1-(1-méthylpipéridin-4-yl)-3-{[4-(2-méthylpropoxy)phényl]méthyl}urée
pimavanserina	1-[(4-fluorofenil)metil]-1-(1-metilpiperidin-4-il)-3-{[4-(2-metilpropoxi)=fenil]metil}urea

$C_{25}H_{34}FN_3O_2$



piragliatinum

piragliatin	(2*R*)-2-[3-chloro-4-(methanesulfonyl)phenyl]-3-[(1*R*)-3-oxocyclopentyl]-*N*-(pyrazin-2-yl)propanamide
piragliatine	(2*R*)-2-[3-chloro-4-(méthanesulfonyl)phényl]-3-[(1*R*)-3-oxocyclopentyl]-*N*-(pyrazin-2-yl)propanamide
piragliatina	(2*R*)-2-[3-cloro-4-(metanosulfonil)fenil]-3-[(1*R*)-3-oxociclopentil]-*N*-(pirazin-2-il)propanamida

$C_{19}H_{20}ClN_3O_4S$



pomalidomidum

pomalidomide	4-amino-2-[(3*RS*)-2,6-dioxopiperidin-3-yl]-2*H*-isoindole-1,3-dione
pomalidomide	4-amino-2-[(3*RS*)-2,6-dioxopipéridin-3-yl]-2*H*-isoindole-1,3-dione
pomalidomida	4-amino-2-[(3*RS*)-2,6-dioxopiperidin-3-il]-2*H*-isoindol-1,3-diona

$C_{13}H_{11}N_3O_4$



and enantiomer
et énantiomère
y enantiómero

posaraprostum

posaraprost — propan-2-yl (5*Z*)-7-{(1*R*,2*S*)-2-[(1*E*,3*S*)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopent-3-en-1-yl}hept-5-enoate

posaraprost — (5*Z*)-7-{(1*R*,2*S*)-2-[(1*E*,3*S*)-3-hydroxy-5-phénylpent-1-én-1-yl]-5-oxocyclopent-3-én-1-yl}hept-5-énoate de propan-2-yle

posaraprost — (5*Z*)-7-{(1*R*,2*S*)-2-[(1*E*,3*S*)-3-hidroxi-5-fenilpent-1-en-1-il]-5-oxociclopent-3-en-1-ilo}-hept-5-enoato de propan-2-ilo

$C_{26}H_{34}O_4$



pyronaridinum

pyronaridine — 4-[(7-chloro-2-methoxybenzo[*b*][1,5]naphthyridin-10-yl)amino]-2,6-bis[(pyrrolidin-1-yl)methyl]phenol

pyronaridine — 4-[(7-chloro-2-méthoxybenzo[*b*][1,5]naphthyridin-10-yl)amino]-2,6-bis[(pyrrolidin-1-yl)méthyl]phénol

pironaridina — 4-[(7-cloro-2-metoxibenzo[*b*][1,5]naftiridin-10-il)amino]-2,6-bis[(pirrolidin-1-il)metil]fenol

$C_{29}H_{32}ClN_5O_2$



rabeximod

rabeximod	2-(9-chloro-2,3-dimethyl-6*H*-indolo[2,3-*b*]quinoxalin-6-yl)-*N*-[2-(dimethylamino)ethyl]acetamide
rabeximod	2-(9-chloro-2,3-diméthyl-6*H*-indolo[2,3-*b*]quinoxalin-6-yl)-*N*-[2-(diméthylamino)éthyl]acétamide
rabeximod	2-(9-cloro-2,3-dimetil-6*H*-indolo[2,3-*b*]quinoxalin-6-il)-*N*-[2-(dimetilamino)etil]acetamida

$C_{22}H_{24}ClN_5O$



raltegravirum

raltegravir	*N*-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-[2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide
raltégravir	*N*-[(4-fluorophényl)méthyl]-5-hydroxy-1-méthyl-2-[2-(5-méthyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide
raltegravir	*N*-[(4-fluorofenil)metil]-5-hidroxi-1-metil-2-[2-(5-metil-1,3,4-oxadiazol-2-carboxamido)propan-2-il]-6-oxo-1,6-dihidropirimidina-4-carboxamida

$C_{20}H_{21}FN_6O_5$



regrelorum

regrelor	N^6-(*N*-ethylcarbamoyl)-2',3'-*O*-[(1*S*,2*E*)-3-phenylprop-2-ene-1,1-diyl]-5'-adenylic acid
régrélor	acide N^6-(*N*-éthylcarbamoyl)-2',3'-*O*-[(1*S*,2*E*)-3-phénylprop-2-ène-1,1-diyl]-5'-adénylique
regrelor	ácido N^6-(*N*-etilcarbamoil)-2',3'-*O*-[(1*S*,2*E*)-3-fenilprop-2-eno-1,1-diilo]-5'-adenílico

$C_{22}H_{25}N_6O_8P$



rolapitantum

rolapitant	(5*S*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
rolapitant	(5*S*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}méthyl)-8-phényl-1,7-diazaspiro[4.5]décan-2-one
rolapitant	(5*S*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi}metil)-8-fenil-1,7-diazaspiro[4.5]decan-2-ona

$C_{25}H_{26}F_6N_2O_2$



romiplostimum*

romiplostim	L-methionyl[human immunogloblin heavy constant gamma 1-(227 *C*-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7':10,10')-bisdisulfide dimer
romiplostim	(7-7':10,10')-bisdisulfure du dimère de la protéine de fusion entre le L-méthionyl[chaine constante gamma 1 de l'immunoglobuline humaine-(227 aminoacides *C*-terminaux)-peptide (fragment Fc)] et un peptide de 41 aminoacides
romiplostim	(7-7':10,10')-bisdisulfuro del dímero de la proteína de fusión entre la L-metionil[cadena constante gamma 1 de la inmunoglobulina humana-(227 aminoácidos *C*-terminales)-péptido (fragmento Fc)] y un péptido de 41 aminoácidos

$C_{2634}H_{4086}N_{722}O_{790}S_{18}$

Monomer / Monomère / Monómero

```
MDKTHTCPPC  PAPELLGGPS  VFLFPPKPKD  TLMISRTPEV  TCVVVDVSHE  50
DPEVKFNWYV  DGVEVHNAKT  KPREEQYNST  YRVVSVLTVL  HQDWLNGKEY  100
KCKVSNKALP  APIEKTISKA  KGQPREPQVY  TLPPSRDELT  KNQVSLTCLV  150
KGFYPSDIAV  EWESNGQPEN  NYKTTPPVLD  SDGSFFLYSK  LTVDKSRWQQ  200
GNVFSCSVMH  EALHNHYTQK  SLSLSPGKGG  GGGIEGPTLR  QWLAARAGGG  250
GGGGGIEGPT  LRQWLAARA                                       269
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

7-7' 10-10' 42-102 42'-102' 148-206 148'-206'

ronacaleretum

ronacaleret — 3-{3-[(2*R*)-3-{[1-(2,3-dihydro-1*H*-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropoxy]-4,5-difluorophenyl}propanoic acid

ronacaléret — acide 3-{3-[(2*R*)-3-{[1-(2,3-dihydro-1*H*-indèn-2-yl)-2-méthylpropan-2-yl]amino}-2-hydroxypropoxy]-4,5-difluorophényl}propanoïque

ronacaleret — ácido3-{3-[(2*R*)-3-{[1-(2,3-dihidro-1*H*-inden-2-il)-2-metilpropan-2-il]amino}-2-hidroxipropoxi]-4,5-difluorofenil}propanoico

$C_{25}H_{31}F_2NO_4$



ropidoxuridinum

ropidoxuridine — 1-(2-deoxy-β-D-*erythro*-pentofuranosyl)-5-iodopyrimidin-2(1*H*)-one

ropidoxuridine — 1-(2-déoxy-β-D-*érythro*-pentofuranosyl)-5-iodopyrimidin-2(1*H*)-one

ropidoxuridina — 1-(2-desoxi-β-D-*eritro*-pentofuranosil)-5-iodopirimidin-2(1*H*)-ona

$C_9H_{11}IN_2O_4$



rosonabantum

rosonabant — (5*RS*)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-*N*-(piperidin-1-yl)-4,5-dihydro-1*H*-pyrazole-3-carboxamide

rosonabant — (5*RS*)-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-*N*-(pipéridin-1-yl)-4,5-dihydro-1*H*-pyrazole-3-carboxamide

rosonabant — (5*RS*)-5-(4-clorofenil)-1-(2,4-diclorofenil)-*N*-(piperidin-1-il)-4,5-dihidro-1*H*-pirazol-3-carboxamida

$C_{21}H_{21}Cl_3N_4O$



and enantiomer
et énantiomère
y enantiómero

salirasibum

salirasib — 2-{[(2*E*,6*E*)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}benzoic acid

salirasib — acide 2-{[(2*E*,6*E*)-3,7,11-triméthyldodéca-2,6,10-trién-1-yl]=sulfanyl}benzoïque

salirasib — ácido 2-{[(2*E*,6*E*)-3,7,11-trimetildodeca-2,6,10-trien-1-il]=sulfanil}benzoico

$C_{22}H_{30}O_2S$



sergliflozinum etabonas

sergliflozin etabonate — 2-[(4-methoxyphenyl)methyl]phenyl 6-*O*-(ethoxycarbonyl)-β-D-glucopyranoside

étabonate de sergliflozine — 6-*O*-(éthoxycarbonyl)-β-D-glucopyranoside de 2-[(4-méthoxyphényl)=méthyl]phényle

etabonato de sergliflozina — 6-*O*-(etoxicarbonil)-β-D-glucopiranósido de 2-[(4-metoxifenil)=metil]fenilo

$C_{23}H_{28}O_9$



sitimagenum ceradenovecum*

sitimagene ceradenovec	(recombinant) replication restricted adenovirus (type 5) vector, E1 and E3 deleted, containing/expressing the *Herpes simplex virus* thymidine kinase (HSV-tk) gene
sitimagène céradénovec	Vecteur adénovirus (type 5 recombinant défectif, délété de E1 et E3, contenant le gène thymidine kinase du virus de l'herpès simplex (*Herpes simplex virus* - HSV-tk)
sitimagén ceradenovec	Vector adenovirus (tipo 5 recombinante defectivo,con deleción de E1 y E3, que contiene el gen timidina kinasa del virus del herpes simplex (*Herpes simplex virus* - HSV-tk)

sotrastaurinum

sotrastaurin	3-(1*H*-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-1*H*-pyrrole-2,5-dione
sotrastaurine	3-(1*H*-indol-3-yl)-4-[2-(4-méthylpipérazin-1-yl)quinazolin-4-yl]-1*H*-pyrrole-2,5-dione
sotrastaurina	3-(1*H*-indol-3-il)-4-[2-(4-metilpiperazin-1-il)quinazolin-4-il]-1*H*-pirrol-2,5-diona

$C_{25}H_{22}N_6O_2$



taranabantum

taranabant	*N*-[(2*S*,3*S*)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl}-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide
taranabant	*N*-[(2*S*,3*S*)-4-(4-chlorophényl)-3-(3-cyanophényl)butan-2-yl}-2-méthyl-2-{[5-(trifluorométhyl)pyridin-2-yl]oxy}propanamide
taranabant	*N*-[(2*S*,3*S*)-4-(4-clorofenil)-3-(3-cianofenil)butan-2-il}-2-metil-2-{[5-(trifluorometil)piridin-2-il]oxi}propanamida

$C_{27}H_{25}ClF_3N_3O_2$



tarenflurbilum

tarenflurbil — (2*R*)-2-(2-fluoro-*[*1,1'-biphenyl-4-yl*]*)propanoic acid

tarenflurbil — acide (2*R*)-2-(2-fluoro-*[*1,1'-biphényl-4-yl*]*)propanoïque

tarenflurbilo — ácido (2*R*)-2-(2-fluoro-*[*1,1'-bifenil-4-il*]*)propanoico

$C_{15}H_{13}FO_2$



teplizumabum*

teplizumab — immunoglobulin G1, anti-[human CD3 epsilon (CD3E)] humanized monoclonal antibody MGA031 [hOKT3gamma1(Ala-Ala)]; gamma1 heavy chain 236L>A, 337L>A [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR from clone OKT3)-*Homo sapiens* IGHG1*01, 117L>A (CH2 1.3), 118L>A (CH2 1.2)] (222-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR from clone OKT3)-*Homo sapiens* IGKC*01] ; (228-228": 231-231")-bisdisulfide dimer

téplizumab — immunoglobuline G1, anti-[CD3 epsilon humain (CD3E)] anticorps monoclonal humanisé MGA031 [hOKT3gamma1(Ala-Ala)]; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone OKT3)-*Homo sapiens* IGHG1*01, 117L >A (CH2 1.3) , 118L>A (CH2 1.2)] (222-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone OKT3)-*Homo sapiens* IGKC*01]; dimère (228-228": 231-231")-bisdisulfure

teplizumab — inmunoglobulina G1, anti-[CD3 epsilon humano (CD3E)] anticuerpo monoclonal humanizado MGA031 [hOKT3gamma1(Ala-Ala)]; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR del clon OKT3)-*Homo sapiens* IGHG1*01, 117L >A (CH2 1.3) , 118L>A (CH2 1.2)] (222-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR del clon OKT3)-*Homo sapiens* IGKC*01]; dímero (228-228": 231-231")-bisdisulfuro

$C_{6462}H_{9938}N_{1738}O_{2022}S_{46}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGGG  VVQPGRSLRL  SCKASGYTFT  RYTMHWVRQA  PGKGLEWIGY  50
INPSRGYTNY  NQKVKDRFTI  SRDNSKNTAF  LQMDSLRPED  TGVYFCARYY  100
DDHYCLDYWG  QGTPVTVSSA  STKGPSVFPL  APSSKSTSGG  TAALGCLVKD  150
YFPEPVTVSW  NSGALTSGVH  TFPAVLQSSG  LYSLSSVVTV  PSSSLGTQTY  200
ICNVNHKPSN  TKVDKKVEPK  SCDKTHTCPP  CPAPEAAGGP  SVFLFPPKPK  250
DTLMISRTPE  VTCVVVDVSH  EDPEVKFNWY  VDGVEVHNAK  TKPREEQYNS  300
TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKAL  PAPIEKTISK  AKGQPREPQV  350
YTLPPSRDEL  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL  400
DSDGSFFLYS  KLTVDKSRWQ  QGNVFSCSVM  HEALHNHYTQ  KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS  LSASVGDRVT  ITCSASSSVS  YMNWYQQTPG  KAPKRWIYDT  50'
SKLASGVPSR  FSGSGSGTDY  TFTISSLQPE  DIATYYCQQW  SSNPFTFGQG  100'
TKLQITRTVA  APSVFIFPPS  DEQLKSGTAS  VVCLLNNFYP  REAKVQWKVD  150'
NALQSGNSQE  SVTEQDSKDS  TYSLSSTLTL  SKADYEKHKV  YACEVTHQGL  200'
SSPVTKSFNR  GEC                                             213'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22''-96''    23'-87'   23'''-87''' 133'-193' 133'''-193''' 146-202 146''-202''
213'-222 213'''-222'' 228-228'' 231-231''   263-323   263''-323''   369-427 369''-427''
```

terameprocolum

terameprocol — 1,1'-[(2*R*,3*S*)-2,3-dimethylbutane-1,4-diyl]bis(3,4-dimethoxybenzene)

térameprocol — 1,1'-[(2*R*,3*S*)-2,3-diméthylbutane-1,4-diyl]bis(3,4-diméthoxybenzène)

terameprocol — 1,1'-[(2*R*,3*S*)-2,3-dimetilbutano-1,4-diil]bis(3,4-dimetoxibenceno)

$C_{22}H_{30}O_4$



thrombinum alfa*

thrombin alfa — human thrombin (recombinant, glycoform α)

thrombine alfa — thrombine humaine (recombinante, glycoforme α)

trombina alfa — trombina humana (recombinante, glicoforma α)

$C_{1511}H_{2342}N_{418}O_{436}S_{15}$

Light chain / Chaîne légère / Cadena ligera

```
TFGSGEADCG  LRPLFEKKSL  EDKTERELLE  SYIDGR                  36
```

Heavy chain / Chaîne lourde / Cadena pesada

```
                                        IVEG  SDAEIGMSPW  50
QVMLFRKSPQ  ELLCGASLIS  DRWVLTAAHC  LLYPPWDKNF  TENDLLVRIG 100
KHSRTRYERN  IEKISMLEKI  YIHPRYNWRE  NLDRDIALMK  LKKPVAFSDY 150
IHPVCLPDRE  TAASLLQAGY  KGRVTGWGNL  KETWTANVGK  GQPSVLQVVN 200
LPIVERPVCK  DSTRIRITDN  MFCAGYKPDE  GKRGDACEGD  SGGPFVMKSP 250
FNNRWYQMGI  VSWGEGCDRD  GKYGFYTHVF  RLKKWIQKVI  DQFGE      295
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
9-155  64-80  209-223  237-267
```

Glycosylation site / Site de glycosylation / Posición de glicosilación

```
Asn-89
```

totrombopagum

totrombopag — (4*Z*)-2-(3,4-dimethylphenyl)-4-(2-{2-hydroxy-3'-(1*H*-tetrazol-5-yl)=[1,1'-biphenyl-3-yl]}hydrazinylidene)-5-methyl-2,4-dihydro-3*H*-pyrazol-3-one

totrombopag — (4*Z*)-2-(3,4-diméthylphényl)-4-{2-[2-hydroxy-3'-(1*H*-tétrazol-5-yl)=[1,1'-biphényl-3-yl]]diazanylidène}-5-méthyl-2,4-dihydro-3*H*-pyrazol-3-one

totrombopag — (4*Z*)-2-(3,4-dimetilfenil)-4-{2-[2-hidroxi-3'-(1*H*-tetrazol-5-il)=[1,1'-bifenil-3-il]]hidrazinilideno}-5-metil-2,4-dihidro-3*H*-pirazol-3-ona

$C_{25}H_{22}N_8O_2$



trabedersenum

trabedersen

2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxyadenosine

trabédersen

2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxyadénosine

trabedersén

2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxiadenosina

$C_{177}H_{225}N_{60}O_{94}P_{17}S_{17}$

trelanserinum

trelanserin

2-(7-fluoro-2-oxo-4-{2-[4-(thieno[3,2-*c*]pyridin-4-yl)piperazin-1-yl]ethyl}-1,2-dihydroquinolin-1-yl)acetamide

trélansérine

2-(7-fluoro-2-oxo-4-{2-[4-(thiéno[3,2-*c*]pyridin-4-yl)pipérazin-1-yl]éthyl}-1,2-dihydroquinolein-1-yl)acétamide

trelanserina

2-(7-fluoro-2-oxo-4-{2-[4-(tieno[3,2-*c*]piridin-4-il)piperazin-1-il]etil}-1,2-dihidroquinolin-1-il)acetamida

$C_{24}H_{24}FN_5O_2S$



tremelimumabum *

tremelimumab — immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain), disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer

trémélimumab — immunoglobuline G2, anti-(protéine 4 cytotoxique du lymphocyte T humain (antigène CD 152)) dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal humain clone 11.2.1 du CP-675206

tremelimumab — inmunoglobulina G2, anti-(proteína 4 citotóxica de linfocitos T humanos (antígeno CD 152)) dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano CP-675206 clon 11.2.1

$C_{6500}H_{9974}N_{1726}O_{2026}S_{52}$

tridecactidum

tridecactide — alpha-1-13-corticotropin, human
L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine

tridécactide — alpha-1-13-corticotropine, humaine
L-séryl-L-tyrosyl-L-séryl-L-méthionyl-L-glutamyl-L-histidyl-L-phénylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine

tridecactida — alfa-1-13-corticotropina, humana
L-seril-L-tirosil-L-seril-L-metionil-L-glutamil-L-histidil-L-fenilalanil-L-arginil-L-triptofilglicil-L-lisil-L-prolil-L-valina

$C_{75}H_{106}N_{20}O_{19}S$

H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-OH
10

tropantiolum

tropantiol — 2-({[(1*R*,2*R*,3*S*,5*S*)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]=octan-2-yl]methyl}{2-[(2-sulfanylethyl)amino]ethyl}amino)ethanethiol

tropantiol — 2-({[(1*R*,2*R*,3*S*,5*S*)-3-(4-chlorophényl)-8-méthyl-8-azabicyclo[3.2.1]=octan-2-yl]méthyl}{2-[(2-sulfanyléthyl)amino]éthyl}amino)éthanethiol

tropantiol — 2-({[(1*R*,2*R*,3*S*,5*S*)-3-(4-clorofenil)- 8-azabiciclo[3.2.1]octan-2-il]metil}{2-[(2-sulfaniletil)amino]etil}amino)etanotiol

$C_{21}H_{34}ClN_3S_2$



vatreptacogum alfa (activatum)*

vatreptacog alfa (activated) — [158-aspartic acid, 296-valine, 298-glutamine]human coagulation factor VII activated, recombinant DNA origin

vatreptacog alfa (activé) — [158-acide aspartique, 296-valine, 298-glutamine]facteur de coagulation VII humain activé, origine ADN recombinant

vatreptacog alfa (activada) — [158-ácido aspártico, 296-valina, 298-glutamina]factor de coagulación VII humano activado ; origen ADN recombinante

$C_{1981}H_{3051}N_{561}O_{620}S_{27}$

Light chain / Chaîne légère / Cadena ligera

```
ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
YCSDHTGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
GR                                                     152
```

Heavy chain / Chaîne lourde / Cadena pesada

```
  IVGGKDCP KGECPWQVLL LVNGAQLCGG TLINTIWVVS AAHCFDKIKN 200
WRNLIAVLGE HDLSEHDGDE QSRRVAQVII PSTYVPGTTN HDIALLRLHQ 250
PVVLTDHVVP LCLPERTFSE RTLAFVRFSL VSGWGQLLDR GATALVLQVL 300
NVPRLMTQDC LQQSRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT 350
HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL 400
LRAPFP                                                 406
```

Modified residues / Résidus modifiés / Residuos modificados

6-7-14-16-19-20-25-26-29-35 E 4-carboxyGlu



D 63 3-hydroxyAsp



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
17-22   50-61   55-70   72-81   91-102  98-112
114-127 135-262 159-164 178-194 310-329 340-368
```

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

```
Ser-52 Ser-60 Asn-145 Asn-322
```

velimogenum aliplasmidum*

velimogene aliplasmid — plasmid DNA vector, expressing HLA-B7 and beta-2 microglobulin, driven by a Rous sarcoma virus promoter

vélimogène aliplasmide — vecteur ADN plasmidique, contenant les gènes HLA-B7 et beta2-microglobuline, sous le contrôle du promoteur virus de sarcome de Rous

velimogén aliplásmido — vector ADN de plásmído, que contiene los genes HLA-B7 y beta2-microglobulina, controlado por el promotor de virus del sarcoma de Rous

voclosporinum

voclosporin — 1,11-anhydro[L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl-[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl][(2*S*)-2-aminobutanoyl]-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucine]

voclosporine — 1,11anhydro{L-alanyl-D-alanyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-valyl-[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-méthyl-2-(méthylamino)nona-6,8-diénoyl]-(2*S*)-2-aminobutanoyl-*N*-méthylglycyl-*N*-méthyl-L-leucyl-L-valyl-*N*-méthyl-L-leucyl]

voclosporina — 1,11-anhidro[L-alanil-D-alanil-*N*-metil-L-leucil-*N*-metil-L-leucil-*N*-metil-L-valil-[(2*S*,3*R*,4*R*,6*E*)-3-hidroxi-4-metil-2-(metilamino)nona-6,8-dienoil][(2*S*)-2-aminobutanoil]-*N*-metilglicil-*N*-metil-L-leucil-L-valil-*N*-methyl-L-leucina]

$C_{63}H_{111}N_{11}O_{12}$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 49
Dénominations communes internationales recommandées (DCI Rec.): Liste 49
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 49
(WHO Drug Information, Vol. 17, No. 2, 2003)

p. 123	*suprimáse*	*insértese*
	garenoxacina	garenoxacino

Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 248 **certolizumabum pegolum**

certolizumab pegol	*insert the following CAS*
certolizumab pégol	*insérer le CAS suivant:*
certolizumab pegol	*insértese el nombre del CAS por el siguiente:*

immunoglobulin, anti-(human tumor necrosis factor α) Fab' fragment (human mouse monoclonal CDP870 heavy chain, disulfide bonded with human mouse monoclonal CDP870 light chain), pegylated at Cys-227 on the heavy chain

immunoglobuline, anti-(facteur α de nécrose tumorale humain) ; (disulfure entre le fragment Fab' de la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris CDP870 humanisé), pégylée à Cyst-227 sur la chaîne lourde

inmunoglobulina, anti-(factor α de necrosis tumoral humano) fragmento Fab' (cadena pesada del anticuerpo monoclonal humanizado de ratón CDP870), disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón CDP870), pegilado Cis-227 de la cadena pesada

Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 61 **beroctocogum alfa***

beroctocog alfa	*replace the chemical structure and molecular formula by the following ones*
béroctocog alfa	*remplacer la structure chimique et la formule brute par les suivantes*
beroctocog alfa	*sustitúyase la fórmula desarrollada y la fórmula molecular por las siguientes*

$C_{3821}H_{5813}N_{1003}O_{1139}S_{35} + C_{3547}H_{5400}N_{956}O_{1033}S_{35}$

human blood-coagulation factor VIII-(1-740)-peptide

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR S          741
```

human blood-coagulation factor VIII-(1649-2332)-peptide

```
                                                    EI 1650
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYSSD VDLEKDVHSG 1850
LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                    2332
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 528-554 1899-1903 2021-2169 2174-2326

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

Modifications / Modifications / Modificaciones
Y = 4-O-sulfotyrosyl

* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.